We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Verizon, Prologis, Medtronic and Crimson
Read MoreHide Full Article
For Immediate Releases
Chicago, IL – September 16, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Verizon Communications Inc. (VZ - Free Report) , Prologis, Inc. (PLD - Free Report) , Medtronic plc (MDT - Free Report) and Crimson Wine Group, Ltd. (CWGL - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Verizon, Prologis and Medtronic
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc., Prologis, Inc. and Medtronic plc, as well as a micro-cap stock Crimson Wine Group, Ltd. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Verizon have gained +22.2% over the year-to-date period against the Zacks Wireless National industry’s gain of +27.7%. The company is likely to benefit from the deployment of a cloud-native, container-based, virtualized architecture for higher flexibility, scalability and cost efficiency across its network.
Customer-focused planning, disciplined engineering and steady infrastructure investments are tailwinds. Various mix-and-match pricing plans in both wireless and home broadband divisions have led to solid client additions.
However, lower wireline and wireless equipment revenues are major concerns. Huge promotional expenses and lucrative discounts to expand customer base are weighing on margins. High capital expenditure for continuous network upgrade and fiber deployment is a headwind. A muted guidance for 2024 is worrisome.
Prologis’ shares have gained +7.9% over the past year period against the Zacks REIT and Equity Trust - Other industry’s gain of +25.7%. The company is well-poised to gain from its portfolio of strategically located industrial facilities in some of the world’s busiest distribution markets. Strategic buyouts and development activities appear promising.
For 2024, we project rental revenues to rise 10.4% year over year. Its scale drives efficiency and a solid balance sheet strength aids its growth endeavors. Industrial real estate market demand is healthy and this trend is expected to continue in the near term. Also, the shrink in the construction pipeline augurs well.
However, amid a volatile environment and geopolitical issues, customers remain focused on cost controls and delaying their leasing decisions. As such, net absorptions are likely to be affected. High interest rates remain a concern. Our estimate indicates a 12.2% year-over-year rise in interest expenses in 2024.t
Shares of Medtronic have gained +13.6% over the past year against the Zacks Medical - Products industry’s gain of +20.2%. The company is strategically expanding its global presence to address the unmet demand for advanced medical devices. Within Cardiovascular, Medtronic is gaining market share, banking on product launches in CRM and Structural Heart.
Hypertension has brought up multibillion-dollar opportunities for MDT. In MedSurg, Medtronic is scaling the production of Hugo RAS. The Surgical and Neuroscience portfolios continues to contribute positively. Further, the company’s Pacing business continued to drive strong growth banking on strong global growth of its Micra leadless pacemaker.
Innovations and market expansion efforts are helping it offset the impact of the inflation and supply disruptions. Medtronic’s strong liquidity position should allow it to meet its near-term debt obligations. All these factors support our bullish stance on the stock.
Crimson Wine’s shares have outperformed the Zacks Beverages - Alcohol industry over the year-to-date period (+0.9% vs. -6.2%). This microcap company with market capitalization of $123.36 million presents a compelling case for investment with its strong portfolio of premium wine estates, including brands like Pine Ridge and Archery Summit, which benefit from sustained demand in the luxury segment.
Crimson Wine boasts a robust balance sheet, with $16.86 million in cash and low debt. Effective cost management, reduced inventory write-downs and a focus on high-margin direct-to-consumer sales bolster the investment thesis.
However, risks include declining sales in both wholesale and direct-to-consumer channels, which fell 5% and 4% year over year, respectively, in second-quarter 2024. Rising operating expenses, increased share repurchases amid falling cash reserves, and exposure to climate risks also weigh on the outlook. Lastly, Crimson is vulnerable to inflation, market conditions and fluctuations in consumer demand for premium wines.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Verizon, Prologis, Medtronic and Crimson
For Immediate Releases
Chicago, IL – September 16, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Verizon Communications Inc. (VZ - Free Report) , Prologis, Inc. (PLD - Free Report) , Medtronic plc (MDT - Free Report) and Crimson Wine Group, Ltd. (CWGL - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Verizon, Prologis and Medtronic
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc., Prologis, Inc. and Medtronic plc, as well as a micro-cap stock Crimson Wine Group, Ltd. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Verizon have gained +22.2% over the year-to-date period against the Zacks Wireless National industry’s gain of +27.7%. The company is likely to benefit from the deployment of a cloud-native, container-based, virtualized architecture for higher flexibility, scalability and cost efficiency across its network.
Customer-focused planning, disciplined engineering and steady infrastructure investments are tailwinds. Various mix-and-match pricing plans in both wireless and home broadband divisions have led to solid client additions.
However, lower wireline and wireless equipment revenues are major concerns. Huge promotional expenses and lucrative discounts to expand customer base are weighing on margins. High capital expenditure for continuous network upgrade and fiber deployment is a headwind. A muted guidance for 2024 is worrisome.
(You can read the full research report on Verizon here >>>)
Prologis’ shares have gained +7.9% over the past year period against the Zacks REIT and Equity Trust - Other industry’s gain of +25.7%. The company is well-poised to gain from its portfolio of strategically located industrial facilities in some of the world’s busiest distribution markets. Strategic buyouts and development activities appear promising.
For 2024, we project rental revenues to rise 10.4% year over year. Its scale drives efficiency and a solid balance sheet strength aids its growth endeavors. Industrial real estate market demand is healthy and this trend is expected to continue in the near term. Also, the shrink in the construction pipeline augurs well.
However, amid a volatile environment and geopolitical issues, customers remain focused on cost controls and delaying their leasing decisions. As such, net absorptions are likely to be affected. High interest rates remain a concern. Our estimate indicates a 12.2% year-over-year rise in interest expenses in 2024.t
(You can read the full research report on Prologis here >>>)
Shares of Medtronic have gained +13.6% over the past year against the Zacks Medical - Products industry’s gain of +20.2%. The company is strategically expanding its global presence to address the unmet demand for advanced medical devices. Within Cardiovascular, Medtronic is gaining market share, banking on product launches in CRM and Structural Heart.
Hypertension has brought up multibillion-dollar opportunities for MDT. In MedSurg, Medtronic is scaling the production of Hugo RAS. The Surgical and Neuroscience portfolios continues to contribute positively. Further, the company’s Pacing business continued to drive strong growth banking on strong global growth of its Micra leadless pacemaker.
Innovations and market expansion efforts are helping it offset the impact of the inflation and supply disruptions. Medtronic’s strong liquidity position should allow it to meet its near-term debt obligations. All these factors support our bullish stance on the stock.
(You can read the full research report on Medtronic here >>>)
Crimson Wine’s shares have outperformed the Zacks Beverages - Alcohol industry over the year-to-date period (+0.9% vs. -6.2%). This microcap company with market capitalization of $123.36 million presents a compelling case for investment with its strong portfolio of premium wine estates, including brands like Pine Ridge and Archery Summit, which benefit from sustained demand in the luxury segment.
Crimson Wine boasts a robust balance sheet, with $16.86 million in cash and low debt. Effective cost management, reduced inventory write-downs and a focus on high-margin direct-to-consumer sales bolster the investment thesis.
However, risks include declining sales in both wholesale and direct-to-consumer channels, which fell 5% and 4% year over year, respectively, in second-quarter 2024. Rising operating expenses, increased share repurchases amid falling cash reserves, and exposure to climate risks also weigh on the outlook. Lastly, Crimson is vulnerable to inflation, market conditions and fluctuations in consumer demand for premium wines.
(You can read the full research report on Crimson Wine here >>>)
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.